5 news items
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
and viral diseases. Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
ALGS
25 Apr 24
. Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
diseases. Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
to become a world leader in the treatment of liver and viral diseases. Aligos' strategy is to harness the deep expertise and decades of drug development
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
ALGS
5 Mar 24
that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos' strategy is to harness the deep
- Prev
- 1
- Next